Pilot Neoadjuvant Study of ZD1839 (IRESSA) as Single Agent Preoperative Therapy for Clinical Stage 1A and 1B (T1-2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC) With Molecular Correlates
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2012
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Jan 2008 The expected completion date for this trial is now 1 Mar 2008.
- 17 Aug 2005 New trial record.